CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
• 作者

  Woan Karrune; Bjordahl Ryan; Cichocki Frank; Gaidarova Svetlana; Pride Cameron; Kaufman Dan S.; Malmberg Karl-Johan; Cooley Sarah; Valamehr Bahram; Miller Jeffrey S.;

  展开▼
• 作者单位

  Univ Minnesota Dept Med Hematol Oncol &

  Transplantat Box 736 UMHC Minneapolis MN 55455 USA;

  Fate Therapeut Inc San Diego CA USA;

  Univ Minnesota Dept Med Hematol Oncol &

  Transplantat Box 736 UMHC Minneapolis MN 55455 USA;

  Fate Therapeut Inc San Diego CA USA;

  Fate Therapeut Inc San Diego CA USA;

  Univ Calif San Diego Dept Med Div Regenerat Med La Jolla CA 92093 USA;

  Karolinska Univ Hosp Huddinge Karolinska Inst Stockholm Sweden;

  Univ Minnesota Dept Med Div Hematol Oncol &

  Transplantat Box 736 UMHC Minneapolis MN 55455 USA;

  Fate Therapeut Inc San Diego CA USA;

  Univ Minnesota Dept Med Hematol Oncol &

  Transplantat Box 736 UMHC Minneapolis MN 55455 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词